These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26821205)

  • 21. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
    Fraillery D; Zosso N; Nardelli-Haefliger D
    Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immune response induced by vaccination with pseudotyped rAAV1 expressing HPV16 L1 protein].
    Zhou YB; Li ZL; Zhou L; Sheng W; Ma HT; Zeng Y
    Bing Du Xue Bao; 2008 Jul; 24(4):300-4. PubMed ID: 18780634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus vaccines.
    Breitburd F; Coursaget P
    Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
    Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
    Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.
    Kuck D; Leder C; Kern A; Müller M; Piuko K; Gissmann L; Kleinschmidt JA
    Vaccine; 2006 Apr; 24(15):2952-65. PubMed ID: 16414157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
    Kim SN; Jeong HS; Park SN; Kim HJ
    J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae.
    Woo MK; Hur SJ; Park S; Kim HJ
    J Microbiol Biotechnol; 2007 Oct; 17(10):1738-41. PubMed ID: 18156796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1.
    Bolhassani A; Shirbaghaee Z; Agi E; Davoudi N
    Protein Expr Purif; 2015 Dec; 116():7-11. PubMed ID: 26304732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice].
    Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.
    Nieto K; Stahl-Hennig C; Leuchs B; Müller M; Gissmann L; Kleinschmidt JA
    Hum Gene Ther; 2012 Jul; 23(7):733-41. PubMed ID: 22401308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector.
    Gao L; Chain B; Sinclair C; Crawford L; Zhou J; Morris J; Zhu X; Stauss H
    J Gen Virol; 1994 Jan; 75 ( Pt 1)():157-64. PubMed ID: 7509369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response.
    Bissa M; Zanotto C; Pacchioni S; Volonté L; Venuti A; Lembo D; De Giuli Morghen C; Radaelli A
    Antiviral Res; 2015 Apr; 116():67-75. PubMed ID: 25660110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Construction of recombinant vaccinia virus expressing HPV18E7E6 fusion proteins and detection of its immunogenicity in mice].
    Zhao L; Ren J; Feng J; Gao J; Zhang H; Tian HW; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Jun; 22(3):189-91. PubMed ID: 19031699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
    Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
    Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.
    Schellenbacher C; Huber B; Skoll M; Shafti-Keramat S; Roden RBS; Kirnbauer R
    Vaccine; 2019 Jun; 37(27):3529-3534. PubMed ID: 31147274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
    Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
    Albarran Y Carvajal A; de la Garza A; Cruz Quiroz BJ; Vazquez Zea E; Díaz Estrada I; Mendez Fuentez E; López Contreras M; Andrade-Manzano A; Padilla S; Varela AR; Rosales R
    BioDrugs; 2007; 21(1):47-59. PubMed ID: 17263589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
    Meseda CA; Stout RR; Weir JP
    Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.